Oncology / Hematology - Department of Internal Medicine III, Ulm, Prof. Dr. med. Hartmut Döhner

About us

The Department of Internal Medicine III has its focus on the treatment of patients for benign and malignant hematological diseases (e.g. anemia, acute and chronic leukemia, myelodysplastic syndromes, myeloproliferative disorders, Hodgkin´s and Non-Hodgkin´s lymphoma, multiple myeloma, aplastic anemia) and for tumors of solid organs (e.g. lung cancer, renal cell carcinoma, breast cancer, glioblastoma, sarcoma and testicular tumors).

The spectrum of treatment comprises all modern therapies, such as conventional chemotherapy, innovative therapies with monoclonal antibodies, and molecular-targeted approaches using newly developed drugs. The Transplant Unit is one of the oldest in the world. For more than 30 years our Department has performed bone marrow and peripheral blood stem cell transplants.

With its 108 beds, an Oncology Outpatient Day Clinic (MOT) and an Outpatient Clinic with specialized consultations, the Department of Internal Medicine III is one of the biggest centres for oncology in Germany. The Department is part of the Comprehensive Cancer Center Ulm (CCCU). All patients with malignant hematological and oncological diseases are discussed by an interdisciplinary team of experts from various fields (tumor board). Treatment strategies follow actual scientific guidelines. The CCCU has been awared by the "Deutsche Krebshilfe" (German Cancer Aid Association) as being one of the 11 leading university centres for oncology.

Our experimental and laboratory research activities focus on the identification, characterization and clinical diagnosis of genetic changes in hematological malignancies, and development of new therapies for hematological and oncological diseases. The Laboratory for Cytogenetic and Molecular Genetic Diagnostics has a high international reputation and is a central reference laboratory for the genetic diagnosis, within a number of multicenter clinical trial groups.

The Department of Internal Medicine III is equipped with a wide spectrum of modern methods in molecular genetics. At the clinical and scientific interface we are entitled to offer a wide spectrum of innovative therapies to our patients.

Our research performance achieves the highest international recognition. The scientific reputation of our staff is outstanding.

Diagnostic Services

• Complete spectrum of diagnostics in internal medicine (e.g. endoscopy, sonography and echocardiography)
• Complete spectrum of diagnostics in radiology and nuclear medicine (incl. PET-CT)
• Complete spectrum of laboratory diagnostics
• Molecular genetic analysis of tumor associated genetic disorders (chromosome analysis, FISH, PCR, DNA sequence analysis, DNA chip analysis)

Therapeutic Services

Our treatment concepts follow the latest national and international standards. The spectrum comprises all modern therapies, such as conventional chemotherapy, innovative therapies with monoclonal antibodies, molecular-targeted approaches as well as autologous and allogeneic blood stem cell transplants.

The Department of Internal Medicine III has a Clinical Trial Unit (CTU). Currently, more than 70 clinical trials of phase I-II (early development of novel and promising anti-cancer agents) and of phase III-IV (randomized treatment trials for optimization and surveillance of therapies) are in operation. A large proportion of patients are treated within such controlled clinical trials, thereby ensuring innovation, highest quality in patient care and early benefit from medical progress.

Special Offers / Arrangements / Rooms

• Buffet breakfast in the ward
• Wireless LAN internet
• Physiotherapy
• Psycho-oncology
• Pastoral care
• Social care assistance for home care and rehabilitation